Your browser doesn't support javascript.
loading
EGFL7 expression profile in IDH-wildtype glioblastomas is associated with poor patient outcome.
da Costa, Bruno Henrique Bressan; Becker, Aline Paixão; Neder, Luciano; Gonçalves, Paola Gyuliane; de Oliveira, Cristiane; Polverini, Allan Dias; Clara, Carlos Afonso; Teixeira, Gustavo Ramos; Reis, Rui Manuel; Bidinotto, Lucas Tadeu.
Afiliação
  • da Costa BHB; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
  • Becker AP; Barretos School of Health Sciences, Dr. Paulo Prata - FACISB, Barretos, São Paulo, Brazil.
  • Neder L; The Ohio State University, Department of Radiation Oncology, Columbus, OH, USA.
  • Gonçalves PG; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
  • de Oliveira C; Department of Pathology, School of Medicine of Ribeirao Preto, University of Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil.
  • Polverini AD; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
  • Clara CA; UNESP - Univ. Estadual Paulista, School of Medicine, Department of Pathology, Botucatu, São Paulo, Brazil.
  • Teixeira GR; Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
  • Reis RM; UNESP - Univ. Estadual Paulista, School of Medicine, Department of Pathology, Botucatu, São Paulo, Brazil.
  • Bidinotto LT; Department of Neurosurgery, Barretos Cancer Hospital, Barretos, São Paulo, Brazil.
J Pathol Transl Med ; 56(4): 205-211, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35698739
BACKGROUND: Despite the advances in glioblastoma (GBM) treatment, the average life span of patients is 14 months. Therefore, it is urgent to identity biomarkers of prognosis, treatment response, or development of novel treatment strategies. We previously described the association of high epidermal growth factor-like domain multiple 7 (EGFL7) expression and unfavorable outcome of pilocytic astrocytoma patients. The present study aims to analyze the prognostic potential of EGFL7 in GBM isocitrate dehydrogenase (IDH)-wildtype, using immunohistochemistry and in silico approaches. METHODS: Spearman's correlation analysis of The Cancer Genome Atlas RNA sequencing data was performed. The genes strongly correlated to EGFL7 expression were submitted to enrichment gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis. Additionally, EGFL7 expression was associated with patient overall survival. The expression of EGFL7 was analyzed through immunohistochemistry in 74 GBM IDH-wildtype patients' samples, and was associated with clinicopathological data and overall survival. RESULTS: In silico analysis found 78 genes strongly correlated to EGFL7 expression. These genes were enriched in 40 biological processes and eight KEGG pathways, including angiogenesis/vasculogenesis, cell adhesion, and phosphoinositide 3-kinase-Akt, Notch, and Rap1 signaling pathways. The immunostaining showed high EGFL7 expression in 39 cases (52.7%). High immunolabelling was significantly associated with low Karnofsky Performance Status and poor overall survival. Cox analysis showed that GBMs IDH-wildtype with high EGFL7 expression presented a higher risk of death compared to low expression (hazard ratio, 1.645; 95% confidence interval, 1.021 to 2.650; p = .041). CONCLUSIONS: This study gives insights regarding the genes that are correlated with EGFL7, as well as biological processes and signaling pathways, which should be further investigated in order to elucidate their role in glioblastoma biology.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article